Freedom To Do More

Bone pain imprisons your patients. Address the pain with tolerability that may not limit other treatment options. QUADRAMET® delivers a short half-life radionuclide that targets multiple lesions with a single injection.

EFFECTIVE PAIN RELIEF

  • 62% to 72% of patients had relief in the first 4 weeks after administration2
  • Patients who respond to QUADRAMET may begin to experience pain relief in one week1

Some patients have reported a transient increase in bone pain within 72 hours of injection (flare reaction) which is usually mild and self-limiting

SIGNIFICANT REDUCTION IN PAIN WITH QUADRAMET

Significant reduction in pain scores.1,3

AUPC Scores

* Statistically significant difference in change from baseline in comparison to placebo group.

  • Maximal pain relief generally occurs at 3 to 4 weeks after injection of QUADRAMET1

REDUCTION IN OPIOID ANALGESIC CONSUMPTION IN TWO PIVOTAL TRIALS2,3

opioid reduction

Patients who experience a reduction in pain may be encouraged to decrease their use of opioid analgesics.

LONG-LASTING RELIEF – AND THE FREEDOM OF A SINGLE INJECTION

  • 16-week duration of pain relief for patients who responded to a single injection of QUADRAMET at
    1.0 mCi/kg.2

Sustained relief with 1.0 mCi/kg QUADRAMET

opioid reduction

Percentage of patients who had relief of pain according to a physician-completed global assessment. Graph adapted from Serafini et al.2

*Statistically significant difference from placebo during the first 4 weeks.2

FREEDOM TO REPEAT TREATMENT OF RECURRENT BONE PAIN

"The pain response after multiple administrations of [Quadramet] is similar to that after an initial administration both in terms of decrease in pain intensity scores and percentage of patients responding."4

Before QUADRAMET is administered, consideration should be given to the patient's current clinical and hematologic status and previous bone marrow response to myelosuppressive treatments.

REFERENCES:

  1. Quadramet® (Samarium Sm 153 Lexidronam Injection) prescribing information. April 2009.
  2. Serafini AN, Houston SJ, Resche I, et al. Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: a double-blind placebo-controlled clinical trial. J Clin Oncol. 1998;16:1574-1581.
  3. Sartor O, Reid RH, Hoskin PJ, et al. Samarium-153-Lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer. Urology. 2004;63:940-945.
  4. Sartor O, Reid RH, Bushnell DL, Quick DP, Ell PJ. Safety and efficacy of repeat administration of samarium Sm-153 lexidronam to patients with metastatic bone pain. Cancer. 2006; Dec 13: [Epub ahead of print].